Preventing metabolic-associated fatty liver disease with fermented cordyceps preparation: an electronic medical record based study
BackgroundMetabolic-associated fatty liver disease (MAFLD) is a prevalent chronic liver condition with significant health implications. Fermented Cordyceps Preparation (FCP) has shown promise in managing metabolic disorders, prompting interest in its potential for MAFLD prevention. There is, however...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1576029/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849727524107452416 |
|---|---|
| author | Xiaozhou Zhou Xiaozhou Zhou Zijian Tian Shaoyun Li Ruifeng Jing Ziqing Liu Peng Wu Jian Shao Jie Bai Jie Bai Rong Huang Ying Pan Kaixin Zhou |
| author_facet | Xiaozhou Zhou Xiaozhou Zhou Zijian Tian Shaoyun Li Ruifeng Jing Ziqing Liu Peng Wu Jian Shao Jie Bai Jie Bai Rong Huang Ying Pan Kaixin Zhou |
| author_sort | Xiaozhou Zhou |
| collection | DOAJ |
| description | BackgroundMetabolic-associated fatty liver disease (MAFLD) is a prevalent chronic liver condition with significant health implications. Fermented Cordyceps Preparation (FCP) has shown promise in managing metabolic disorders, prompting interest in its potential for MAFLD prevention. There is, however, a lack of large-scale clinical evidence regarding its preventive efficacy and long-term safety.AimWe aimed to assess the preventive efficacy and safety of FCP, as regards combatting MAFLD.MethodsPropensity score matching was used to select 343 FCP users and 1372 non-users with metabolic syndrome, (MS) as recorded in EMR. These two groups were followed for 750 days, to track the incidence of MAFLD. The Kaplan Meier method was used to calculate the cumulative risk of MAFLD events in each subgroup. A Multiple linear regression model was used to compare the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as between the two groups.ResultsCompared with non-users, FCP users were associated with a 26% decreased risk of MAFLD (hazard ratio 0.74, 95% confidence interval 0.56–0.97). During the follow-up, the changes in both ALT and AST, were insignificantly different between the two groups.ConclusionThese findings highlight the potential of FCP in MAFLD prevention and offer insight into its safety profile, suggesting avenues for further clinical validation and drug repurposing efforts. |
| format | Article |
| id | doaj-art-829b0627ef454f3cada9ec4b5c3bfc0c |
| institution | DOAJ |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-829b0627ef454f3cada9ec4b5c3bfc0c2025-08-20T03:09:48ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-05-011210.3389/fmed.2025.15760291576029Preventing metabolic-associated fatty liver disease with fermented cordyceps preparation: an electronic medical record based studyXiaozhou Zhou0Xiaozhou Zhou1Zijian Tian2Shaoyun Li3Ruifeng Jing4Ziqing Liu5Peng Wu6Jian Shao7Jie Bai8Jie Bai9Rong Huang10Ying Pan11Kaixin Zhou12College of Life Sciences, University of Chinese Academy of Sciences, Beijing, ChinaGuangzhou National Laboratory, Guangzhou, Guangdong, ChinaNational Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences (CAS), Beijing, ChinaFifth People’s Hospital of Chongqing, Chongqing, ChinaGuangzhou National Laboratory, Guangzhou, Guangdong, ChinaGuangzhou National Laboratory, Guangzhou, Guangdong, ChinaCollege of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, ChinaGuangzhou National Laboratory, Guangzhou, Guangdong, ChinaGuangzhou National Laboratory, Guangzhou, Guangdong, ChinaCollege of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, ChinaCentral Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, ChinaDepartment of General Practice, Kunshan Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu, ChinaGuangzhou National Laboratory, Guangzhou, Guangdong, ChinaBackgroundMetabolic-associated fatty liver disease (MAFLD) is a prevalent chronic liver condition with significant health implications. Fermented Cordyceps Preparation (FCP) has shown promise in managing metabolic disorders, prompting interest in its potential for MAFLD prevention. There is, however, a lack of large-scale clinical evidence regarding its preventive efficacy and long-term safety.AimWe aimed to assess the preventive efficacy and safety of FCP, as regards combatting MAFLD.MethodsPropensity score matching was used to select 343 FCP users and 1372 non-users with metabolic syndrome, (MS) as recorded in EMR. These two groups were followed for 750 days, to track the incidence of MAFLD. The Kaplan Meier method was used to calculate the cumulative risk of MAFLD events in each subgroup. A Multiple linear regression model was used to compare the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as between the two groups.ResultsCompared with non-users, FCP users were associated with a 26% decreased risk of MAFLD (hazard ratio 0.74, 95% confidence interval 0.56–0.97). During the follow-up, the changes in both ALT and AST, were insignificantly different between the two groups.ConclusionThese findings highlight the potential of FCP in MAFLD prevention and offer insight into its safety profile, suggesting avenues for further clinical validation and drug repurposing efforts.https://www.frontiersin.org/articles/10.3389/fmed.2025.1576029/fullMAFLDFermented Cordyceps Preparationmetabolic syndromeefficacysafety |
| spellingShingle | Xiaozhou Zhou Xiaozhou Zhou Zijian Tian Shaoyun Li Ruifeng Jing Ziqing Liu Peng Wu Jian Shao Jie Bai Jie Bai Rong Huang Ying Pan Kaixin Zhou Preventing metabolic-associated fatty liver disease with fermented cordyceps preparation: an electronic medical record based study Frontiers in Medicine MAFLD Fermented Cordyceps Preparation metabolic syndrome efficacy safety |
| title | Preventing metabolic-associated fatty liver disease with fermented cordyceps preparation: an electronic medical record based study |
| title_full | Preventing metabolic-associated fatty liver disease with fermented cordyceps preparation: an electronic medical record based study |
| title_fullStr | Preventing metabolic-associated fatty liver disease with fermented cordyceps preparation: an electronic medical record based study |
| title_full_unstemmed | Preventing metabolic-associated fatty liver disease with fermented cordyceps preparation: an electronic medical record based study |
| title_short | Preventing metabolic-associated fatty liver disease with fermented cordyceps preparation: an electronic medical record based study |
| title_sort | preventing metabolic associated fatty liver disease with fermented cordyceps preparation an electronic medical record based study |
| topic | MAFLD Fermented Cordyceps Preparation metabolic syndrome efficacy safety |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1576029/full |
| work_keys_str_mv | AT xiaozhouzhou preventingmetabolicassociatedfattyliverdiseasewithfermentedcordycepspreparationanelectronicmedicalrecordbasedstudy AT xiaozhouzhou preventingmetabolicassociatedfattyliverdiseasewithfermentedcordycepspreparationanelectronicmedicalrecordbasedstudy AT zijiantian preventingmetabolicassociatedfattyliverdiseasewithfermentedcordycepspreparationanelectronicmedicalrecordbasedstudy AT shaoyunli preventingmetabolicassociatedfattyliverdiseasewithfermentedcordycepspreparationanelectronicmedicalrecordbasedstudy AT ruifengjing preventingmetabolicassociatedfattyliverdiseasewithfermentedcordycepspreparationanelectronicmedicalrecordbasedstudy AT ziqingliu preventingmetabolicassociatedfattyliverdiseasewithfermentedcordycepspreparationanelectronicmedicalrecordbasedstudy AT pengwu preventingmetabolicassociatedfattyliverdiseasewithfermentedcordycepspreparationanelectronicmedicalrecordbasedstudy AT jianshao preventingmetabolicassociatedfattyliverdiseasewithfermentedcordycepspreparationanelectronicmedicalrecordbasedstudy AT jiebai preventingmetabolicassociatedfattyliverdiseasewithfermentedcordycepspreparationanelectronicmedicalrecordbasedstudy AT jiebai preventingmetabolicassociatedfattyliverdiseasewithfermentedcordycepspreparationanelectronicmedicalrecordbasedstudy AT ronghuang preventingmetabolicassociatedfattyliverdiseasewithfermentedcordycepspreparationanelectronicmedicalrecordbasedstudy AT yingpan preventingmetabolicassociatedfattyliverdiseasewithfermentedcordycepspreparationanelectronicmedicalrecordbasedstudy AT kaixinzhou preventingmetabolicassociatedfattyliverdiseasewithfermentedcordycepspreparationanelectronicmedicalrecordbasedstudy |